Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 13/20 | 0.56 |
| ▸ | ACHE | P22303 | 13/20 | 0.56 |
| ▸ | EHMT2 | Q96KQ7 | 2/20 | 0.52 |
| ▸ | EHMT1 | Q9H9B1 | 2/20 | 0.52 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.50 |
| ▸ | EGFR | P00533 | 1/20 | 0.50 |
| ▸ | KDR | P35968 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19260771 | 0.93 | BCHE (0.55) | BCHEACHEEHMT2EHMT1MCHR1 | |
| SCHEMBL20745310 | 0.80 | KDM4E (0.71) | MAPT | |
| SCHEMBL19260705 | 0.79 | HTR4 (0.56) | ACHEEHMT2EHMT1 | |
| SCHEMBL27814877 | 0.77 | LMNA (0.55) | EGFRKDRMAPT | |
| SCHEMBL19260648 | 0.75 | EHMT2 (0.53) | BCHEACHEEHMT2EHMT1MCHR1 | |
| SCHEMBL7838137 | 0.75 | KDM4E (0.61) | ACHEEHMT2EHMT1MAPT | |
| Hydrochloric Acid SCHEMBL2920128 | 0.74 | KDM4E (0.60) | ACHEEHMT2EHMT1MAPT | |
| SCHEMBL7206125 | 0.74 | ACHE (0.64) | BCHEACHEMCHR1 | |
| SCHEMBL19260656 | 0.73 | KDM4E (0.59) | EHMT2EHMT1 | |
| SCHEMBL11336084 | 0.73 | MAPT (0.76) | MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11254651-B2 | Histone methyltransferase inhibitors | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2022-02-22 | — | — | US | disclosed |
| EP-3416963-B1 | HISTONE METHYLTRANSFERASE INHIBITORS | GLOBAL BLOOD THERAPEUTICS INC (US) | 2021-07-28 | — | — | EP | disclosed |
| US-20190047981-A1 | HISTONE METHYLTRANSFERASE INHIBITORS | GLOBAL BLOOD THERAPEUTICS, INC. | 2019-02-14 | — | — | US | disclosed |
| EP-3416963-A1 | HISTONE METHYLTRANSFERASE INHIBITORS | Global Blood Therapeutics, Inc. (US) | 2018-12-26 | — | — | EP | disclosed |
| WO-2017142947-A1 | HISTONE METHYLTRANSFERASE INHIBITORS | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2017-08-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190047981-A1 | HISTONE METHYLTRANSFERASE INHIBITORS | EHMT1, EHMT2, BMI1 | BCHE 1184/4885ACHE 3056/4885EHMT2 2/4885 |
| US-11254651-B2 | Histone methyltransferase inhibitors | EHMT1, EHMT2, BMI1 | BCHE 1184/4885ACHE 3056/4885EHMT2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.